Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Melanoma/Skin Cancers

Type: Oral Abstract Session

Time: Tuesday June 4, 9:45 AM to 12:45 PM

Location: S406

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Advanced Disease

Melanoma/Skin Cancers

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr 9501)

Author(s): Hussein Abdul-Hassan Tawbi, Peter A. J. Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Parada Thomas, John A. Glaspy, Sekwon Jang, Alain Patrick Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Agnes Balogh, Jasmine I. Rizzo, Kim Allyson Margolin; The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Dana-Farber Cancer Institute, Boston, MA; University of Michigan, Ann Arbor, MI; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; The Angeles Clinic and Research Institute, Los Angeles, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; University of Colorado Comprehensive Cancer Center, Aurora, CO; Stanford University Hospital, Palo Alto, CA; Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Inova Schar Cancer Institute, Virginia Commonwealth University, Fairfax, VA; University of California, San Francisco, San Francisco, CA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Bristol-Myers Squibb, Princeton, NJ; City of Hope, Duarte, CA

Abstract Disclosures


Background: We previously reported efficacy and safety of NIVO+IPI in patients (pts) with untreated, asymptomatic, melanoma brain metastases (MBM) from the CheckMate 204 study. Here, we provide the first report of NIVO+IPI in pts with symptomatic MBM, and report updated data in pts with asymptomatic MBM. Methods: In this phase II trial, pts with ≥1 measurable, nonirradiated MBM 0.5–3.0 cm were enrolled into two cohorts: (1) those with no neurologic symptoms or steroid Rx (asymptomatic; cohort A); and (2) those with neurologic symptoms, whether or not they were receiving steroid Rx (symptomatic; cohort B). In both cohorts, pts received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4, then NIVO 3 mg/kg Q2W until progression or toxicity. The primary endpoint was intracranial clinical benefit rate (CBR; proportion of pts with complete response [CR] + partial response [PR] + stable disease [SD] ≥6 mo). As of the clinical cutoff date on May 1, 2018, all treated pts (101 in cohort A and 18 in cohort B) had been followed for ~6 mo or longer. Results: In this updated analysis of cohort A (median follow-up of 20.6 mo), the CBR was 58.4% (Table). In cohort B, pts received a median of 1 NIVO+IPI dose and 2 of 18 pts (11%) received all 4 doses. At a median follow-up of 5.2 months in cohort B, intracranial objective response rate was 16.7% and the CBR was 22.2%. Grade 3/4 adverse events occurred in 54.5% of pts in cohort A and in 55.6% of pts in cohort B (6.9% and 16.7% in the nervous system, respectively), with one death related to treatment in cohort A (immune-related myocarditis). Conclusions: In pts with asymptomatic MBM, our updated results show a high rate of durable intracranial responses, further supporting NIVO+IPI as a first-line treatment in this population. Intracranial antitumor activity was observed with NIVO+IPI in pts with symptomatic MBM, but further study is needed to understand the biologic mechanisms of resistance to immunotherapy and to improve treatments in this challenging population. Clinical trial information: NCT02320058

Intracranial responseAsymptomatic
(Cohort A; n = 101)
(Cohort B; n = 18)
 Best overall response, n (%)
 CR29 (29)2 (11)
 PR26 (26)1 (5.6)
 SD ≥6 mo4 (4)1 (5.6)
CBR, % (95% CI)58.4 (48.2–68.1)22.2 (6.4–47.6)

Other Abstracts in this Sub-Category:


1. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9500 First Author: Gerald Fogarty
Category: Melanoma/Skin Cancers - Advanced Disease


2. Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9505 First Author: Michael Weichenthal
Category: Melanoma/Skin Cancers - Advanced Disease


3. Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9506 First Author: Daniel Olson
Category: Melanoma/Skin Cancers - Advanced Disease